Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseasesLabel,2. It is marketed under the name EliquisLabel,3. Apixaban was approved by the FDA on December 28, 20123.
Previous: Apixaban intermediate cas 27143-07-3
Next: Tianeptine is an antidepressant agent
Related Industry Information